RZLT

Rezolute, Inc. [RZLT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

RZLT Stock Summary

Top 10 Correlated ETFs

RZLT

Top 10 Correlated Stocks

RZLT

In the News

RZLT Financial details

Company Rating
-
Market Cap
106.99M
Income
-56.85M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
57
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.03
Forward P/E
-
PEG
0.22
P/S
-
P/B
0.56
P/C
-
P/FCF
-0.94
Quick Ratio
13.72
Current Ratio
14.27
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.11
EPS next Y
-
EPS next Q
-
EPS this Y
-52.58%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-3.57%
-
-
-
-
SMA20
18.9%
SMA50
49.66%
SMA100
-10.33%
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
-46%
ROC
-0.58%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.72-2.7492
52W High
-
52W Low
-
RSI
55.02
Rel Volume
1.05
Avg Volume
326.82K
Volume
342.85K
Perf Week
-1.18%
Perf Month
6.06%
Perf Quarter
2.94%
Perf Half Y
-14.98%
-
-
-
-
Beta
1.325
-
-
Volatility
0.07%, 0.29%
Prev Close
-4.55%
Price
4.2
Change
-2.33%

Something similar

Top by Market Cap
NVDA
MSF.DE
GOOGL
FXAIX
META
Top Correlated ETFs
SBIO
ROX.DE
BIOT.L
EZA
GWX
Top Correlated Stocks
REPL
IDYA
CGEM
AGIO
AUTL
Similar Market Cap
PCQ
NAK
FXB
AUID
HBIO

Company Profile

Healthcare Biotechnology
  • Volume Average 326.82K
  • Market Capitalization 106.99M
  • Employee 57
  • CEO Mr. Nevan Charles Elam J.D.
  • Headquarters Redwood City,CA,US
  • IPO Date 2013-01-14
  • Website https://www.rezolutebio.com

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.